Adalimumab for Immunotherapy-Related Arthritis
Treatments studied
Part of Bones, joints & muscles clinical trials.
This study tests if a medicine called adalimumab (a type of TNF blocker) can help with new joint pain and swelling (inflammatory arthritis) caused by some immunotherapy drugs. It aims to reduce the need for high-dose steroids and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have new joint swelling or pain (inflammatory arthritis) that started within the last 6 months while taking or soon after stopping a cancer immunotherapy drug (like a PD-1 or CTLA-4 blocker).
- You have needed at least 10 mg of prednisone daily (or a similar steroid) for your arthritis, or have tried to cut down on steroids but the arthritis came back.
- You do not have a previous diagnosis of a different type of arthritis (like rheumatoid arthritis or psoriatic arthritis) before this episode.
- You do not have a current infection like tuberculosis, hepatitis, or HIV, or a history of heart failure or certain nerve disorders.
- You have not used a TNF inhibitor (like adalimumab or etanercept) in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if checking the amount of adalimumab (a biologic drug) in your blood can help doctors safely lower your dose. If you have had rheumatoid arthritis under control for at least 6 months, this trial may help you take less medication while keeping symptoms away.
This trial studies how doctors assess and manage immune-related arthritis or joint pain that happens after PD-1/PD-L1 cancer immunotherapy (sometimes with CTLA-4). It may help people get faster, more targeted care while monitoring safety.
This trial compares two medicine options (azathioprine vs methotrexate) when added to adalimumab to treat active Crohn’s disease. It may help determine which add-on works better for people whose Crohn’s is still active despite standard treatments or who can’t take them.
This study looks at how your immune system responds to starting infliximab or adalimumab for rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Results may help doctors understand why some people don’t respond as well and how to improve treatment.
This Phase 4 trial studies whether immune-modulator medicines improve symptoms and function in people with rheumatoid arthritis who have knee problems. It may also compare responses in osteoarthritis and healthy volunteers, depending on the group you fit.
This trial tests whether the drug infliximab can help treat kidney damage caused by immunotherapy (checkpoint inhibitors). It is for people whose kidneys suddenly fail due to inflammation, and who haven't already had strong immune-suppressing treatment for this problem.
Hear when a new Inflammatory Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.